Proactive Investors speaks with Kazia CEO Dr James Garner
Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.
The interview covers:
An overview of Kazia and its programs – GDC-0084 for glioblastoma, the most common and aggressive form of brain cancer, and Cantrixil for ovarian cancer
How GDC-0084 works by targeting the PI3K control mechanism, which has been shown to work well in other forms of cancer, but uniquely in our drug, also crosses the brain cancer
How Cantrixil works by targeting cancer stem cells in patients with platinum resistant ovarian cancer
Expected data read out points for 2019 across both GDC-0084 and Cantrixil